



Glorenta

A Novel Approach for Diabetes Management

Objective:

Case

SGLT2 Inhibitor & DPP-4 inhibitor introduction

SGLT2 Inhibitor & DPP-4 inhibitor mode of action

Combination therapy

Efficacy & Safety studies of Glorenta

FDA label

Conclusion

Case

- **Background**

- A 56 y/o woman who suffers from **type 2 DM** for 15 years

- **Medical History**

- **Hypertension** since 20 years ago
- **CCU admission**

- **Surgical History**

- C-section 20 years ago

- **Social History**

- House wife

- **Physical Exam**

- BMI: 24 kg/m²
- BP: 150/100 mmHg

Lab Summary		
Glycemia	FBS	186 mg/dl
	HbA1c	8 %
Lipid profile	Total Chol	210 mg/dl
	HDL-C	30 mg/dl
	LDL-C	100 mg/dl
	TG	400 mg/dl
Renal Function	UACR	25 mg/gr
	eGFR	86 ml/min/1.73m ²
	Cr	0.8 mg/dl

Current Medications	Metformin 1000 mg/daily
	Empagliflozin 10 mg/daily
	Losartan 25 mg/daily
	ASA 80 mg/daily

Case



What Is the Most Appropriate Treatment for Glycemic Control?

- A. Maximize metformin therapy
- B. Switch to combination therapy
(Metformin 1000 mg & Empagliflozin 5 mg) BD
- C. Add Diabezid to current therapy
- D. Maximize metformin therapy and add DPP4i
- E. Maximize metformin therapy and add combination of
Empagliflozin 25 mg and Linagliptin 5 mg once daily

Patient History

- 56 Y/O female, **T2DM**, **HTN**, **CCU admission** history
- FBS: **186** mg/dl
- HbA1c: **8** %
- eGFR: **86** ml/min/1.73 m²
- UACR: **25** mg/g
- Cr: **0.8** mg/dl
- Total Chol: **210** mg/dl TG: **400** mg/dl
- HDL-C: **30** mg/dl LDL-C: **100** mg/dl
- Medications: **Metformin 1000 mg/daily;**
Empagliflozin 10 mg/daily; Losartan 25mg/daily;
ASA 80 mg/daily
- BMI: **24** kg/m²
- BP: **150/100** mmHg

Making a Choice between Agents?



Sometimes DPP-4 inhibitor is a Good Choice

Glycemic control¹
weight neutral¹
Lower risk of hypoglycemia¹
Tolerability priority¹
CV safety¹

DPP-4 inhibitor

SGLT2 inhibitor

1. Capuano A, et al. Drug Design Dev Ther 2013;7:989-1001.

Sometimes SGLT2 inhibitor is a Good Choice

Efficient HbA1c reduction¹

Weight loss priority¹

Reduction in BP¹

CV protection effect¹

Renal protection effect¹

DPP-4 inhibitor

SGLT2 inhibitor

1. Zinman B et al. N Engl J Med , (2015), 9-1-15

How a bout Using Both?

Robust lowering of HbA1c¹⁻³

FPG significant reduction¹⁻³

Low Hypoglycemia ratio¹⁻³

Weight loss¹⁻³

Reduction in BP¹⁻³

Well tolerated¹⁻³

DPP-4 inhibitor

+

SGLT2 inhibitor

1. DeFronzo et al. (2015). Diabetes Care ;38:384 2. Tan et al. (2016). Annales d'Endocrinologie, 77(5): 557–562


3. Lewin et al. (2015). Diabetes Care , 38(3):394-402



Glorenta

Empagliflozin / Linagliptin

DPP-4 inhibitors Provide an Effective Pharmacological Approach in T2DM ¹⁻⁴



By increasing and prolonging active incretin levels, Linagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner.


DPP-4=dipeptidyl peptidase 4; GI=gastrointestinal; GIP=glucose-dependent insulinotropic peptide; GLP-1=glucagon-like peptide-1.

^aIncretin hormones GLP-1 and GIP are released by the intestine throughout the day, and their levels increase in response to a meal.

1. Kieffer TJ et al. *Endocr Rev.* 1999;20(6):876–913. 2. Ahrén B. *Curr Diab Rep.* 2003;3(5):365–372. 3. Drucker DJ. *Diabetes Care.* 2003;26(10):2929–2940. 4. Holst JJ. *Diabetes Metab Res Rev.* 2002;18(6):430–441.

Urinary glucose excretion via SGLT2 inhibition

SGLT2 inhibitors work by inhibiting reabsorption of glucose in the kidney¹




SGLT1, sodium-glucose co-transporter-1, SGLT2, sodium-glucose co-transporter-2

1. Bakris GL et al. Kidney Int 2009;75;1272

Maintaining glycemic targets can be difficult to achieve


A significant number of patients with T2D have poor glycemic control ¹



**Target HbA_{1c}
6.5–7%***


**Glycemic targets should be individualised ^{3,4}*

Glycemic control tends to decline over time with monotherapy ²




1. JAMA 2004; 291:335; 2. JAMA 1999; 281:2005; 3. Diab Vasc Dis Res 2009; 6:283; 4. Diabetes Care 2015; 38:140

The sequential treatment approach is compounded by substantial inertia to timely intensification of therapy ^{1,2}



Trends in Fixed Dose Combination Drug Development for Diabetes by Global Status¹




1. Buse JB (2017). The Future of Combination Therapy in the Treatment of Type 2 Diabetes—Which Classes, Why, and When? Presented at the American Diabetes Association Scientific Sessions, San Diego, CA.


Guidelines: initial combination therapy recommendations



If A1C values are $\geq 1.5\%$ above target ²





If A1C values are $\geq 7.5-9\%$ ¹



If A1C values are $\geq 1.5-2\%$ above target ³

1. Endocr Pract 2020;26 (No. 1)
2. Can J Diabetes 2018; 42, S88–S103
3. Diabetes Care 43, Supplement 1, January 2020

Improving Glycemic Control in T2DM Achieving Glycemic Goals Sooner May Reduce the Risk of Complications ^{1,2}



Conservative vs. proactive management: (A) **traditional stepwise approach** and (B) **early combination approach**. OAD, oral antidiabetic drug

1. Int J Clin Pract 2005; 59:1345–1355. 2. BMJ 2000; 321:405–412.


Advantages of Fixed dose combination

- Improving patient adherence and compliance by reducing polypharmacy.^{1,2}
- Improving quality of life and tolerability.¹
- Improving Lower overall costs.³
- Synergistic effect.⁴
- Lower doses of different components.⁴

1. Adv Ther 2012; 29:993-1004; 2. The American Journal of Medicine 2007; 120, 713-719; 3. Diabetes Obes Metab. 2013;15(4): 291–300;

4. Archives of Pharmacal Research 2016; 39(6), 731–746.

Better adherence to oral glucose-lowering therapy is associated with better glycaemic control¹



1. Diabetes UK. Diabetic Medicine 2010; 27, 739–743




Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin

*Ralph A. DeFronzo,¹ Andrew Lewin,²
Sanjay Patel,³ Dacheng Liu,⁴ Renee Kaste,⁴
Hans J. Woerle,⁵ and Uli C. Broed⁵*

DOI: 10.2337/dc14-2364

Study Design



DeFronzo et al. (2015). Diabetes Care ;38:384

Objective & End point

OBJECTIVE:

- ❖ To evaluate the efficacy and safety of empagliflozin/linagliptin in subjects with type 2 diabetes.

Primary end point:

- ❖ Change from baseline in HbA1c at week 24

Key Secondary end point:


- ❖ Change from baseline in FPG at week 24
- ❖ Change from baseline in body weight at week 24
- ❖ proportion of subjects with baseline HbA1c $\geq 7\%$ (≥ 53 mmol/mol) who had HbA1c $< 7\%$ (< 53 mmol/mol) at week 24.

Objective & End point Cont.

Exploratory end points:


- ❖ Change from baseline in HbA1c at week 24 in subgroups of subjects with HbA1c ≥ 8.5 and $< 8.5\%$ at baseline.
- ❖ Change from baseline in HbA1c, FPG, weight, systolic blood pressure (SBP), and diastolic blood pressure (DBP) at week 52.
- ❖ Proportion of subjects with baseline HbA1c $\geq 7\%$ (≥ 53 mmol/mol) who had HbA1c $< 7\%$ (< 53 mmol/mol) at week 52.

Change from Baseline in HbA1c at Week 24¹




1. DeFronzo et al. (2015). *Diabetes Care* ;38:384

Patients with HbA1c $\geq 7\%$ at baseline who had HbA1c $< 7\%$ at week 24¹




1. DeFronzo et al. (2015). Diabetes Care ;38:384

Patients with HbA1c $\geq 7\%$ at baseline who had HbA1c $< 7\%$ at week 52¹




1. DeFronzo et al. (2015). Diabetes Care ;38:384

Change in HbA_{1c} at Week 24 in Patients with HbA_{1c} ≥8.5%¹



1. DeFronzo et al. (2015). Diabetes Care ;38:384


Combination of Empagliflozin+Linagliptin Demonstrates Early and Durable Achievement of Goal¹



* ADA recommends an A1C target of <7%. Individual goal of patient should be determined by their physician². Change from baseline vs individual components, $p < 0.0001$.¹


1. DeFronzo et al. (2015). Diabetes Care ;38:384 2. ADA Standards of Medical Care 2018

Change from Baseline in FPG at Week 24¹



1. DeFronzo et al. (2015). Diabetes Care ;38:384



Change from baseline in body weight at Week 24¹



❖ *Empagliflozin + Linagliptin (Glorenta) is not indicated for weight reduction*

1. DeFronzo et al. (2015). Diabetes Care ;38:384

Change from baseline in BP (mmHg) at Week 52¹



1. DeFronzo et al. (2015). Diabetes Care ;38:384

Conclusion¹

- ❑ The combination of empagliflozin +linagliptin led to significantly greater reductions in glycated hemoglobin (HbA1c) and fasting plasma glucose compared with either drug alone over 24 weeks¹.
- ❑ T2DM patients treated with the drug combination were >3 times more likely to achieve HbA1c <7% than those on either monotherapy¹.
- ❑ Weight reduction was significantly greater in the combination group only when compared with linagliptin monotherapy¹.
- ❑ Safety profile was similar between combination treatment and monotherapies¹.
- ❑ This combination, administered once daily, can reduce regimen complexity, enhance adherence and improve outcomes in clinical practice¹.
- ❑ With the use of FDCs, polypharmacy, fear for side effects, cost, and clinical (therapeutic) inertia both from patients and physicians can be minimized and patient adherence to treatment can be improved, thereby increasing the likelihood of achieving treatment goals¹.

1. Diabetes, Obes Metab, 2020; 22(6):1001-1005

Conclusion

Combination of empagliflozin/linagliptin:

- ❖ Significantly Reduced HbA1c compared with the individual components and were well tolerated.
- ❖ FPG was significantly reduced with empagliflozin 25 mg/linagliptin 5mg compared with individual components
- ❖ The combination of empagliflozin and linagliptin added on to metformin offered a sustained reduction in HbA1c, FPG, weight, and blood pressure, which persisted up to week 52.

Dosage and Administration (Once Daily Tablet)¹

- Recommended starting dose: 10/5mg (10mg Empagliflozin/ 5mg Linagliptin).
- Do not initiate GLORENTA if eGFR is below 45 mL/min/1.73 m².
- Discontinue GLORENTA if eGFR falls persistently below 45 mL/min/1.73 m².

1. GLYXAMBI® (empagliflozin and linagliptin) tablets label FDA 2018



Limitation of Use ¹

Not recommended for:

- Patients with type 1 diabetes
- Patients with history of pancreatitis
- The treatment of diabetic ketoacidosis

1. GLYXAMBI® (empagliflozin and linagliptin) tablets label FDA 2018

Contraindications ¹

1. Severe renal impairment, end-stage renal disease or dialysis
2. History of serious hypersensitivity reaction to empagliflozin, linagliptin:
 - Anaphylaxis
 - Angioedema
 - Exfoliative skin conditions
 - Urticaria

1. GLYXAMBI® (empagliflozin and linagliptin) tablets label FDA 2018

Adverse Reactions¹

- Urinary tract infections
- Upper respiratory tract infections
- Nasopharyngitis

1. GLYXAMBI® (empagliflozin and linagliptin) tablets label FDA 2018

Use in Specific Communication¹

- Pregnancy
- Lactation
- Pediatric Patients
- Geriatric Patients

1. GLYXAMBI® (empagliflozin and linagliptin) tablets label FDA 2018

Conclusions¹

Glorenta as the combination of Gloripa & Lirenta with their complementary mechanisms of action:

- Is the only OAD that has compelling and relevant CVOT data among its individual components:
 - Gloripa, the only OAD indicated to reduce cardiovascular death in T2D among ASCVD patients.
 - Lirenta, which is proven CV safe among patients with CV risks and renal disease
- Provides a powerful HbA1c reduction, effective glycemic control and weight loss compared to the individual components, with a low risk of hypoglycemia

1. DeFronzo et al. (2015). Diabetes Care ;38:384



Thank you